Screening people at higher risk of Parkinson's disease over time
Screens people at raised risk of Parkinson's disease and follows them for years.
Plain-language title generated from the registry record
Registry title: Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
Key facts
- Where
- Kiel, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 99 years old?
Source: NCT04724941, who can take part
Where in Germany
- Department for Neurology, University of KielKiel, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital Schleswig-Holstein
- Trial code
- NCT04724941
- Record updated
- 22 September 2025
- Original description
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.Read full original descriptionShow less
Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study
The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.
Inclusion: Age between 50 and 99.
Exclusion: Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis); other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment; in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants); Presence of clinical PD at the time of study inclusion.